Investigational approaches to therapies for idiopathic pulmonary fibrosis

Bibliography

• Paget J. Lectures on surgical pathology delivered at the Royal College of Surgeons of England. Wilson and Ogilvy, London, UK; 1853
   Google Scholar
• Bucala R, Spiegel L, Chesney J, Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol Med 1994;1:71-81
   PubMed Web of Science ®Google Scholar
• Chesney J, Bacher M, Bender A, Bucala R. The peripheral blood fibrocyte is a potent antigen-presenting cell capable of priming naive T cells in situ. Proc Natl Acad Sci USA 1997;19(12):6307
   Web of Science ®Google Scholar
• Chesney J, Metz C, Stavitsky AB, Regulated production of type I collagen and inflammatory cytokines by peripheral blood fibrocytes. J Immunol 1998;160(1):419-25
   PubMed Web of Science ®Google Scholar
• Abe R, Donnelly SC, Peng T, Peripheral blood fibrocytes: differentiation pathway and migration to wound sites. J Immunol 2001;166(12):7556-62
   PubMed Web of Science ®Google Scholar
• Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008;134(6):1655-69
   PubMed Web of Science ®Google Scholar
• Lin SL, Kisseleva T, Brenner DA, Duffield JS. Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney. Am J Pathol 2008;173(6):1617-27
   PubMed Web of Science ®Google Scholar
• Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009;119(6):1420-8
   PubMed Web of Science ®Google Scholar
• Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009;139(5):871-90
   PubMed Web of Science ®Google Scholar
• Wynn TA. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol 2004;4(8):583
   PubMed Web of Science ®Google Scholar
• Lupher ML Jr, Gallatin WM. Regulation of fibrosis by the immune system. Adv Immunol 2006;89:245-88
   PubMed Web of Science ®Google Scholar
• Schmidt M, Sun G, Stacey MA, Identification of circulating fibrocytes as precursors of bronchial myofibroblasts in asthma. J Immunol 2003;171(1):380-9
   PubMed Web of Science ®Google Scholar
• Olson AL, Swigris JJ, Lezotte DC, Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am J Respir Crit Care Med 2007;176(3):277-84
   PubMed Web of Science ®Google Scholar
• Douglas WW, Ryu JH, Schroeder DR. Idiopathic pulmonary fibrosis: Impact of oxygen and colchicine, prednisone, or no therapy on survival. Am J Respir Crit Care Med 2000;161(4 Pt 1):1172-8
   PubMed Web of Science ®Google Scholar
• Schmidt SL, Sundaram B, Flaherty KR. Diagnosing fibrotic lung disease: when is high-resolution computed tomography sufficient to make a diagnosis of idiopathic pulmonary fibrosis? Respirology 2009;14(7):934-9
   PubMed Web of Science ®Google Scholar
• Chua F, Gauldie J, Laurent GJ. Pulmonary fibrosis: searching for model answers. Am J Respir Cell Mol Biol 2005;33(1):9-13
   PubMed Web of Science ®Google Scholar
• Hanak V, Ryu JH, de Carvalho E, Profusion of fibroblast foci in patients with idiopathic pulmonary fibrosis does not predict outcome. Respir Med 2008;102(6):852-6
   PubMed Web of Science ®Google Scholar
• Konishi K, Gibson KF, Lindell KO, Gene expression profiles of acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009;180(2):167-75
   PubMed Web of Science ®Google Scholar
• Strieter RM, Mehrad B. New mechanisms of pulmonary fibrosis. Chest 2009;136(5):1364-70
   PubMed Web of Science ®Google Scholar
• du Bois RM. Strategies for treating idiopathic pulmonary fibrosis. Nat Rev Drug Discov 2010;9(2):129-40
   PubMed Web of Science ®Google Scholar
• Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001;134(2):136-51
   PubMed Web of Science ®Google Scholar
• Davies HR, Richeldi L. Idiopathic pulmonary fibrosis: current and future treatment options. Am J Respir Med 2002;1(3):211-24
   PubMedGoogle Scholar
• Fiorucci E, Lucantoni G, Paone G, Colchicine, cyclophosphamide and prednisone in the treatment of mild-moderate idiopathic pulmonary fibrosis: comparison of three currently available therapeutic regimens. Eur Rev Med Pharmacol Sci 2008;12(2):105-11
   PubMed Web of Science ®Google Scholar
• King TE Jr, Albera C, Bradford WZ, Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 2009;374(9685):222-8
   PubMed Web of Science ®Google Scholar
• Prasse A, Muller-Quernheim J. Non-invasive biomarkers in pulmonary fibrosis. Respirology 2009;14(6):788-95
   PubMed Web of Science ®Google Scholar
• Brook NR, Waller JR, Bicknell GR, Nicholson ML. The experimental agent pirfenidone reduces pro-fibrotic gene expression in a model of tacrolimus-induced nephrotoxicity. J Surg Res 2005;125(2):137-43
   PubMed Web of Science ®Google Scholar
• Iyer SN, Hyde DM, Giri SN. Anti-inflammatory effect of pirfenidone in the bleomycin-hamster model of lung inflammation. Inflammation 2000;24(5):477-91
   PubMed Web of Science ®Google Scholar
• Oku H, Shimizu T, Kawabata T, Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol 2008;590(1-3):400-8
   PubMed Web of Science ®Google Scholar
• Mansoor JK, Decile KC, Giri SN, Influence of pirfenidone on airway hyperresponsiveness and inflammation in a Brown-Norway rat model of asthma. Pulm Pharmacol Therp 2007;20(6):660-8
   PubMed Web of Science ®Google Scholar
• Tian XL, Yao W, Guo ZJ, Low dose pirfenidone suppresses transforming growth factor beta-1 and tissue inhibitor of metalloproteinase-1, and protects rats from lung fibrosis induced by bleomycina. Chin Med Sci J 2006;21(3):145-51
   PubMedGoogle Scholar
• Schelegle ES, Mansoor JK, Giri S. Pirfenidone attenuates bleomycin-induced changes in pulmonary functions in hamsters. Proc Soc Exp Biol Med 1997;216(3):392-7
   PubMed Web of Science ®Google Scholar
• Kehrer JP, Margolin SB. Pirfenidone diminishes cyclophosphamide-induced lung fibrosis in mice. Toxicol Lett 1997;90(2-3):125-32
   PubMed Web of Science ®Google Scholar
• Iyer SN, Wild JS, Schiedt MJ, Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters. J Lab Clin Med 1995;125(6):779-85
   PubMed Web of Science ®Google Scholar
• Wang F, Wen T, Chen XY, Wu H. Protective effects of pirfenidone on D-galactosamine and lipopolysaccharide-induced acute hepatotoxicity in rats. Inflamm Res 2008;57(4):183-8
   PubMed Web of Science ®Google Scholar
• Di Sario A, Bendia E, Macarri G, The anti-fibrotic effect of pirfenidone in rat liver fibrosis is mediated by downregulation of procollagen alpha1(I), TIMP-1 and MMP-2. Dig Liver Dis 2004;36(11):744-51
   PubMedGoogle Scholar
• Kaibori M, Yanagida H, Yokoigawa N, Effects of pirfenidone on endotoxin-induced liver injury after partial hepatectomy in rats. Transplant Proc 2004;36(7):1975-6
   PubMed Web of Science ®Google Scholar
• Kaibori M, Yanagida H, Uchida Y, Pirfenidone protects endotoxin-induced liver injury after hepatic ischemia in rats. Transplant Proc 2004;36(7):1973-4
   PubMed Web of Science ®Google Scholar
• Tsuchiya H, Kaibori M, Yanagida H, Pirfenidone prevents endotoxin-induced liver injury after partial hepatectomy in rats. J Hepatol 2004;40(1):94-101
   PubMed Web of Science ®Google Scholar
• Garcia L, Hernandez I, Sandoval A, Pirfenidone effectively reverses experimental liver fibrosis. J Hepatol 2002;37(6):797-805
   PubMed Web of Science ®Google Scholar
• Oku H, Nakazato H, Horikawa T, Pirfenidone suppresses tumor necrosis factor-alpha, enhances interleukin-10 and protects mice from endotoxic shock. Eur J Pharmacol 2002;446(1-3):167-76
   PubMed Web of Science ®Google Scholar
• Tada S, Nakamuta M, Enjoji M, Pirfenidone inhibits dimethylnitrosamine-induced hepatic fibrosis in rats. Clin Exp Pharmacol Physiol 2001;28(7):522-7
   PubMed Web of Science ®Google Scholar
• Schroll S, Arzt M, Sebah D, Improvement of bleomycin-induced pulmonary hypertension and pulmonary fibrosis by the endothelin receptor antagonist Bosentan. Respir Physiol Neurobiol 2010;170(1):32-6
   Google Scholar
• Mutsaers SE, Marshall RP, Goldsack NR, Effect of endothelin receptor antagonists (BQ-485, Ro 47-0203) on collagen deposition during the development of bleomycin-induced pulmonary fibrosis in rats. Pulm Pharmacol Ther 1998;11(2-3):221-5
   PubMed Web of Science ®Google Scholar
• Park SH, Saleh D, Giaid A, Michel RP. Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist. Am J Respir Crit Care Med 1997;156(2 Pt 1):600-8
   PubMed Web of Science ®Google Scholar
• Available from: www.clinicaltrials.gov
   Google Scholar
• Atkuri KR, Mantovani JJ, Herzenberg LA. N-Acetylcysteine-a safe antidote for cysteine/glutathione deficiency. Curr Opin Pharmacol 2007;7(4):355-9
   PubMed Web of Science ®Google Scholar
• Demedts M, Behr J, Buhl R, High-dose acetylcysteine in idiopathic pulmonary fibrosis. New Engl J Med 2005;353(21):2229-42
   PubMed Web of Science ®Google Scholar
• Rempe S, Hayden JM, Robbins RA, Hoyt JC. Tetracyclines and pulmonary inflammation. Endocr Metab Immune Disord Drug Targets 2007;7(4):232-6
   PubMedGoogle Scholar
• Lettieri CJ, Nathan SD, Barnett SD, Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 2006;129(3):746-52
   PubMed Web of Science ®Google Scholar
• Collard HR, Anstrom KJ, Schwarz MI, Zisman DA. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest 2007;131(3):897-9
   PubMed Web of Science ®Google Scholar
• Jackson RM, Glassberg MK, Ramos CF, Sildenafil therapy and exercise tolerance in idiopathic pulmonary fibrosis. Lung 2010;188(2):115-23
   PubMed Web of Science ®Google Scholar
• Tabata C, Tabata R, Kadokawa Y, Thalidomide prevents bleomycin-induced pulmonary fibrosis in mice. J Immunol 2007;179(1):708-14
   PubMed Web of Science ®Google Scholar
• Horton MR, Danoff SK, Lechtzin N. Thalidomide inhibits the intractable cough of idiopathic pulmonary fibrosis. Thorax 2008;63(8):749
   PubMed Web of Science ®Google Scholar
• Hetzel M, Bachem M, Anders D, Different effects of growth factors on proliferation and matrix production of normal and fibrotic human lung fibroblasts. Lung 2005;183(4):225-37
   PubMed Web of Science ®Google Scholar
• Li M, Abdollahi A, Grone HJ, Late treatment with imatinib mesylate ameliorates radiation-induced lung fibrosis in a mouse model. Radiat Oncol 2009;4:66
   PubMed Web of Science ®Google Scholar
• Vuorinen K, Gao F, Oury TD, Imatinib mesylate inhibits fibrogenesis in asbestos-induced interstitial pneumonia. Exp Lung Res 2007;33(7):357-73
   PubMed Web of Science ®Google Scholar
• Chaudhary NI, Roth GJ, Hilberg F, Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur Respir J 2007;29(5):976-85
   PubMed Web of Science ®Google Scholar
• Aono Y, Nishioka Y, Inayama M, Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice. Am J Respir Crit Care Med 2005;171(11):1279-85
   PubMed Web of Science ®Google Scholar
• Daniels CE, Wilkes MC, Edens M, Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 2004;114(9):1308-16
   PubMed Web of Science ®Google Scholar
• Daniels CE, Lasky JA, Limper AH, randomized placebo-controlled trial results. Am J Respir Crit Care Med 2010;181(6):604-10
   PubMed Web of Science ®Google Scholar
• Fichtner-Feigl S, Strober W, Kawakami K, IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med 2006;12(1):99-106
   PubMed Web of Science ®Google Scholar
• Raghu G, Brown KK, Costabel U, Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med 2008;178(9):948-55
   PubMed Web of Science ®Google Scholar
• Wilborn J, Bailie M, Coffey M, Constitutive activation of 5-lipoxygenase in the lungs of patients with idiopathic pulmonary fibrosis. J Clin Invest 1996;97(8):1827-36
   PubMed Web of Science ®Google Scholar
• Failla M, Genovese T, Mazzon E, Pharmacological inhibition of leukotrienes in an animal model of bleomycin-induced acute lung injury. Respir Res 2006;7:137
   PubMed Web of Science ®Google Scholar
• Khan G, Merajver S. Copper chelation in cancer therapy using tetrathiomolybdate: an evolving paradigm. Expert Opin Investig Drugs 2009;18(4):541-8
   PubMed Web of Science ®Google Scholar
• Brewer GJ, Ullenbruch MR, Dick R, Tetrathiomolybdate therapy protects against bleomycin-induced pulmonary fibrosis in mice. J Lab Clin Med 2003;141(3):210-6
   PubMed Web of Science ®Google Scholar
• Brewer GJ, Dick R, Ullenbruch MR, Inhibition of key cytokines by tetrathiomolybdate in the bleomycin model of pulmonary fibrosis. J Inorg Biochem 2004;98(12):2160-7
   PubMed Web of Science ®Google Scholar
• Shinoda H, Tasaka S, Fujishima S, Elevated CC chemokine level in bronchoalveolar lavage fluid is predictive of a poor outcome of idiopathic pulmonary fibrosis. Respiration 2009;78(3):285-92
   PubMed Web of Science ®Google Scholar
• Car BD, Meloni F, Luisetti M, Elevated IL-8 and MCP-1 in the bronchoalveolar lavage fluid of patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis. Am J Respir Crit Care Med 1994;149(3 Pt 1):655-9
   PubMed Web of Science ®Google Scholar
• Capelli A, Di Stefano A, Gnemmi I, Donner CF. CCR5 expression and CC chemokine levels in idiopathic pulmonary fibrosis. Eur Respir J 2005;25(4):701-7
   PubMed Web of Science ®Google Scholar
• Suga M, Iyonaga K, Ichiyasu H, Clinical significance of MCP-1 levels in BALF and serum in patients with interstitial lung diseases. Eur Respir J 1999;14(2):376-82
   PubMed Web of Science ®Google Scholar
• Murray LA, Argentieri RL, Farrell FX, Hyper-responsiveness of IPF/UIP fibroblasts: interplay between TGFbeta1, IL-13 and CCL2. Int J Biochem Cell Biol 2008;40(10):2174-82
   PubMed Web of Science ®Google Scholar
• Lebtahi R, Moreau S, Marchand-Adam S, Increased uptake of 111In-octreotide in idiopathic pulmonary fibrosis. J Nucl Med 2006;47(8):1281-7
   PubMed Web of Science ®Google Scholar
• Khalil N, O'Connor RN, Unruh HW, Increased production and immunohistochemical localization of transforming growth factor-beta in idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 1991;5(2):155-62
   PubMed Web of Science ®Google Scholar
• Frazier K, Williams S, Kothapalli D, Stimulation of fibroblast cell growth, matrix production, and granulation tissue formation by connective tissue growth factor. J Invest Dermatol 1996;107(3):404-11
   PubMed Web of Science ®Google Scholar
• Lasky JA, Ortiz LA, Tonthat B, Connective tissue growth factor mRNA expression is upregulated in bleomycin-induced lung fibrosis. Am J Physiol 1998;275(2 Pt 1):L365-71
   PubMed Web of Science ®Google Scholar
• Pilling D, Buckley CD, Salmon M, Gomer RH. Inhibition of fibrocyte differentiation by serum amyloid P. J Immunol 2003;171(10):5537-46
   PubMed Web of Science ®Google Scholar
• Haudek SB, Xia Y, Huebener P, Bone marrow-derived fibroblast precursors mediate ischemic cardiomyopathy in mice. Proc Natl Acad Sci USA 2006;103(48):18284-9
   PubMed Web of Science ®Google Scholar
• Pilling D, Roife D, Wang M, Reduction of bleomycin-induced pulmonary fibrosis by serum amyloid P. J Immunol 2007;179(6):4035-44
   PubMed Web of Science ®Google Scholar
• Naik-Mathuria B, Pilling D, Crawford JR, Serum amyloid P inhibits dermal wound healing. Wound Repair Regen 2008;16(2):266-73
   PubMed Web of Science ®Google Scholar
• Lin SL, Castano AP, Nowlin BT, Bone marrow Ly6Chigh monocytes are selectively recruited to injured kidney and differentiate into functionally distinct populations. J Immunol 2009;183(10):6733-43
   PubMed Web of Science ®Google Scholar
• Raghu G, Weycker D, Edelsberg J, Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006;174(7):810-6
   PubMed Web of Science ®Google Scholar
• Robinson D Jr, Eisenberg D, Nietert PJ, Systemic sclerosis prevalence and comorbidities in the US, 2001 – 2002. Curr Med Res Opin 2008;24(4):1157-66
   PubMed Web of Science ®Google Scholar
• McNearney TA, Reveille JD, Fischbach M, Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors. Arthritis Rheum 2007;57(2):318-26
   PubMed Web of Science ®Google Scholar
• Zureik M, Neukirch C, Leynaert B, Sensitisation to airborne moulds and severity of asthma: cross sectional study from European community respiratory health survey. BMJ 2002;325(7361):411-4
   PubMed Web of Science ®Google Scholar